GlaxoSmithKline Pakistan (KAR:GLAXO) Cyclically Adjusted Revenue per Share: ₨158.19 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:GLAXO GlaxoSmithKline Pakistan Ltd KAR:GLAXO
93 GF Score
Price ₨366.07
GF Value ₨323.86
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pakistan Cyclically Adjusted Revenue per Share?

GlaxoSmithKline Pakistan KAR:GLAXO -1.86% 93 Cyclically Adjusted Revenue per Share is ₨158.19 as of Mar. 2026. GuruFocus rates KAR:GLAXO with a GF Score™ of 93/100 and a GF Value™ of ₨323.86 (Modestly Overvalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

GlaxoSmithKline Pakistan's adjusted revenue per share for the three months ended in Mar. 2026 was ₨53.470. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₨158.19 for the trailing ten years ended in Mar. 2026.

During the past 12 months, GlaxoSmithKline Pakistan's average Cyclically Adjusted Revenue Growth Rate was 10.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of GlaxoSmithKline Pakistan was 9.60% per year. The lowest was 9.50% per year. And the median was 9.55% per year.

As of today (2026-07-14), GlaxoSmithKline Pakistan's current stock price is ₨366.07. GlaxoSmithKline Pakistan's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₨158.19. GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio of today is 2.31.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GlaxoSmithKline Pakistan was 3.13. The lowest was 0.58. And the median was 1.26.


GlaxoSmithKline Pakistan  (KAR:GLAXO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=366.07/158.19
=2.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GlaxoSmithKline Pakistan was 3.13. The lowest was 0.58. And the median was 1.26.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


GlaxoSmithKline Pakistan Cyclically Adjusted Revenue per Share Related Terms


GlaxoSmithKline Pakistan Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pakistan's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pakistan Cyclically Adjusted Revenue per Share Chart

GlaxoSmithKline Pakistan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 105.34 115.87 125.01 138.34 152.60

GlaxoSmithKline Pakistan Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 142.63 145.96 148.94 152.60 158.19

KAR:GLAXO vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Pakistan Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio falls into.


KAR:GLAXO
93GF Score
GlaxoSmithKline Pakistan Ltd KAR:GLAXO
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pakistan Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GlaxoSmithKline Pakistan's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=53.47/330.2130*330.2130
=53.470

Current CPI (Mar. 2026) = 330.2130.

GlaxoSmithKline Pakistan Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 21.498 241.018 29.454
201609 21.766 241.428 29.770
201612 24.223 241.432 33.130
201703 26.342 243.801 35.679
201706 24.594 244.955 33.154
201709 24.077 246.819 32.212
201712 27.918 246.524 37.395
201803 28.645 249.554 37.903
201806 25.343 251.989 33.210
201809 25.293 252.439 33.086
201812 27.421 251.233 36.041
201903 26.276 254.202 34.133
201906 29.078 256.143 37.487
201909 25.653 256.759 32.992
201912 33.777 256.974 43.404
202003 25.227 258.115 32.274
202006 24.319 257.797 31.150
202009 33.990 260.280 43.123
202012 26.706 260.474 33.856
202103 24.158 264.877 30.117
202106 28.443 271.696 34.569
202109 30.827 274.310 37.109
202112 31.664 278.802 37.503
202203 27.086 287.504 31.110
202206 29.963 296.311 33.391
202209 37.703 296.808 41.946
202212 36.888 296.797 41.041
202303 35.794 301.836 39.159
202306 37.242 305.109 40.306
202309 43.409 307.789 46.572
202312 39.663 306.746 42.697
202403 49.035 312.332 51.842
202406 41.621 314.175 43.746
202409 46.246 315.301 48.433
202412 55.220 315.605 57.776
202503 48.922 319.799 50.515
202506 46.224 322.561 47.321
202509 44.571 324.800 45.314
202512 67.235 324.054 68.513
202603 53.470 330.213 53.470

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₨158.19 mean?
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Cyclically Adjusted Revenue per Share of ₨158.19 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on GlaxoSmithKline Pakistan and its competitors.
Is GlaxoSmithKline Pakistan's Cyclically Adjusted Revenue per Share too high?
GlaxoSmithKline Pakistan's current Cyclically Adjusted Revenue per Share is ₨158.19. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
GlaxoSmithKline Pakistan's Cyclically Adjusted Revenue per Share of ₨158.19 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on GlaxoSmithKline Pakistan and its competitors. GlaxoSmithKline Pakistan's current Cyclically Adjusted Revenue per Share is ₨158.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨323.86, compared to a current price of ₨366.07 — trading 13% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₨158.19. GlaxoSmithKline Pakistan's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Cyclically Adjusted Revenue per Share is ₨158.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued. The current stock price of ₨366.07 is trading 13% above its estimated GF Value™ of ₨323.86. GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.

Key valuation signals for KAR:GLAXO:

  • Cyclically Adjusted Revenue per Share: ₨158.19
  • GF Value™: ₨323.86 vs. price of ₨366.07 (13% above fair value)
  • GF Score™: 93/100 with 1 warning sign

No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GlaxoSmithKline Pakistan Business Description

Address 35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
93GF Score

Get the complete analysis for KAR:GLAXO

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨366.07
Price
₨323.86
GF Value